Research programme: cholesterol transport modulators - Gilead Sciences
Alternative Names: CVT-10176; CVT-11130Latest Information Update: 15 Mar 2010
At a glance
- Originator CV Therapeutics
- Developer Gilead Sciences
- Class
- Mechanism of Action Apolipoprotein A-I stimulants; ATP binding cassette transporter 1 stimulants; Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Tangier disease
Most Recent Events
- 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences
- 15 Jun 2007 This programme is still in active development
- 06 Jan 2000 Preclinical development for Atherosclerosis in USA (Unknown route)